Skip to main content

Market Overview

CVS Health Debuts $100M Venture Capital Fund For Early-Stage Health Care Companies

CVS Health Debuts $100M Venture Capital Fund For Early-Stage Health Care Companies

CVS Health (NYSE: CVS) has inaugurated CVS Health Ventures, a corporate venture capital fund aimed at creating partnerships with early-stage companies focused on improving the accessibility and affordability of health care.

What Happened: According to the Woonsocket, Rhode Island-based company, the fund will begin with $100 million allocated for investments. The initial targets for the fund will encompass companies in digital health care.

The fund is a continuation of earlier investments and partnerships for CVS Health, which has made more than 20 direct investments through its CVS and Aetna businesses.

Among the companies receiving investments from CVS Health are Unite Us, a technology platform that connects health care and social services providers, and LumiraDx, a point-of-care diagnostic platform.

See Also: Ask The VC with Jeff Ransdell: Investing In Telehealth

What Else Happened: Separately, CVS Health also announced it began administering COVID-19 vaccines at employer-based vaccination clinics through Return Ready, the company’s configurable COVID-19 testing solution for the workplace and college campuses.

CVS Health began Return Ready in February with Delta Air Lines, Inc. (NYSE: DAL) and is now managing employer vaccination clinics for 18 employers across 51 locations, including the International Longshoremen's Association and the municipal government in Philadelphia.

(Photo by Tumisu/Pixabay)


Related Articles (CVS)

View Comments and Join the Discussion!

Posted-In: undefinedNews Health Care Financing General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at